Aerie Pharmaceuticals announces FDA approval of Rhopressa

Aerie Pharmaceuticals recently announced the FDA approval of Rhopressa, a first-in-class therapy for the treatment of patients with open-angle glaucoma and other diseases of the eye.

Rhopressa (netarsudil ophthalmic solution 0.02%) is a once-daily eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension. The drop was approved by the FDA ahead of the scheduled Prescription Drug User Fee Act date of Feb. 28, 2018, according to a company release.

The therapy is believed to reduce IOP by increasing outflow of aqueous humor through the trabecular meshwork, according to Aerie Pharmaceuticals.

“The approval of once-daily Rhopressa represents the single greatest achievement in Aerie’s history to date, and represents exciting news for patients with open-angle glaucoma or ocular hypertension, and physicians. It is a testament to years of successful research and development and the incredible talents of our dedicated employees, to whom we owe much gratitude. We have been preparing for commercialization for well over a year, and our plans are clear. We will hire our sales force of 100 sales representatives early in the first quarter of 2018, and plan to launch by mid-second quarter of 2018," Vicente Anido, Jr., PhD, chairman and CEO at Aerie, said in a company press release.

 

Aerie Pharmaceuticals recently announced the FDA approval of Rhopressa, a first-in-class therapy for the treatment of patients with open-angle glaucoma and other diseases of the eye.

Rhopressa (netarsudil ophthalmic solution 0.02%) is a once-daily eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension. The drop was approved by the FDA ahead of the scheduled Prescription Drug User Fee Act date of Feb. 28, 2018, according to a company release.

The therapy is believed to reduce IOP by increasing outflow of aqueous humor through the trabecular meshwork, according to Aerie Pharmaceuticals.

“The approval of once-daily Rhopressa represents the single greatest achievement in Aerie’s history to date, and represents exciting news for patients with open-angle glaucoma or ocular hypertension, and physicians. It is a testament to years of successful research and development and the incredible talents of our dedicated employees, to whom we owe much gratitude. We have been preparing for commercialization for well over a year, and our plans are clear. We will hire our sales force of 100 sales representatives early in the first quarter of 2018, and plan to launch by mid-second quarter of 2018," Vicente Anido, Jr., PhD, chairman and CEO at Aerie, said in a company press release.